After a forbidding couple of years, the biopharma dealmaking environment is showing signs of life in 2024. Partnering is approaching pre-pandemic levels, M&A activity is surging and deal values are inching up.
It’s not all good news for bootstrapping biotechs, however, as the volume of deals actually fell in 2023, indicating that large pharmas are willing to splash out for the right platform or asset but remain very selective in placing their bets.
This new report from Clarivate, Where pharma is investing for the future of medicine: biopharma deal making in 2024, explores trends in dealmaking, including:
- Which platforms and technologies pharmas are investing in, from antibody drug conjugates to artificial intelligence
- The geographical scope of dealmaking and what it tells us about global innovation clusters
- How pharmas and biotechs can maximize opportunities and minimize risk in order to realize the next generation of breakthrough medical innovations
